Patients with Persistent Polyclonal B-Cell Lymphocytosis Share the Symptomatic Criteria of Systemic Exertion Intolerance Disease.

chronic fatigue syndrome myalgic encephalomyelitis patient opinion persistent polyclonal B-cell lymphocytosis systemic exertion intolerance disease

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
29 Jul 2021
Historique:
received: 01 07 2021
revised: 22 07 2021
accepted: 27 07 2021
entrez: 7 8 2021
pubmed: 8 8 2021
medline: 8 8 2021
Statut: epublish

Résumé

Persistent polyclonal B-cell lymphocytosis (PPBL) is a rare and still poorly understood entity, with 90% of cases occurring in female smokers. Patients often appear tired and in pain, but the clinical symptoms remain imprecise. The main risk is the development of lymphoma in some cases. To better understand the characteristics of the fatigue associated with PPBL and study its relationship with systemic exertion intolerance disease (SEID), we analyzed the symptoms in a cohort of patients with PPBL included in the French national registry. An anonymous questionnaire following the recommendations of the Institute of Medicine/National Academy of Medicine for screening of the new SEID criteria was created in French and mailed to 50 patients. Thirty-nine (78%) contacted patients responded. The studied population was mainly constituted of women (90%) with an average age of 50 (18-59) years. Smoking was a constant factor in all patients. A total of 28/39 (72%) respondents met the SEID symptoms criteria. Severe chronic fatigue for more than 6 months was noted in 36/39 cases (92%). Unrefreshing sleep, post-exertional malaise, cognitive impairment, and orthostatic intolerance were described in 30/39 (77%), 32/39 (82%), 28/39 (72%), and 27/39 (69%) cases, respectively. Pain (arthralgia, myalgia, headache) was present in 26/39 (67%) cases. The most prominent SEID symptoms were fatigue, followed by post-exercise discomfort and cognitive difficulties. The most disabling symptom was non-restorative sleep, followed by pain. An inflammatory and/or autoimmune context was noted in 13 patients (33%), and these comorbidities could have favored the deterioration of the general condition. Three patients also presented with fibromyalgia. However, 3 patients did not mention any complaints. This survey indicated that patients with PPBL most often initially presented with disabling chronic fatigue, chronic pain, and other symptoms suggestive of SEID but requiring more studies to confirm it. Education of medical staff about the symptoms of PPBL should be encouraged to better assess this peculiar condition.

Identifiants

pubmed: 34362156
pii: jcm10153374
doi: 10.3390/jcm10153374
pmc: PMC8347138
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

SRL Neurol Neurosurg. 2017;3(1):22-27
pubmed: 28603794
N Engl J Med. 1982 Jul 22;307(4):232-6
pubmed: 6979709
Presse Med. 1997 Oct 25;26(32):1531
pubmed: 9435835
Rev Med Interne. 2016 Dec;37(12):811-819
pubmed: 27260787
Mod Pathol. 2004 Sep;17(9):1087-96
pubmed: 15143340
BMC Res Notes. 2016 Mar 02;9:138
pubmed: 26935937
BMJ Paediatr Open. 2018 Mar 16;2(1):e000233
pubmed: 29637195
Curr Med Res Opin. 2015;31(7):1333-47
pubmed: 25912615
Ann Hematol. 2006 Dec;85(12):893-6
pubmed: 16988824
Fatigue. 2015 Jul;3(3):127-141
pubmed: 26345409
Leukemia. 2009 Feb;23(2):419-22
pubmed: 18668130
Br J Haematol. 1999 Mar;104(3):486-93
pubmed: 10086784
Popul Health Metr. 2007 Jun 08;5:5
pubmed: 17559660
Onco Targets Ther. 2008 Oct 01;1:59-66
pubmed: 21127753
Leuk Lymphoma. 1996 Jan;20(3-4):267-73
pubmed: 8624466
Ann Intern Med. 1994 Dec 15;121(12):953-9
pubmed: 7978722
Ann Intern Med. 2015 Jun 16;162(12):834-40
pubmed: 26075754
J Intern Med. 2011 Oct;270(4):327-38
pubmed: 21777306
Br J Haematol. 1997 Dec;99(3):531-6
pubmed: 9401061
Ann Hematol. 2008 Oct;87(10):829-36
pubmed: 18587574
Blood. 2011 Dec 15;118(25):6485
pubmed: 22279623

Auteurs

Romain Morizot (R)

Services d'Hématologie Clinique et Biologique, CHRU de Nancy, Université de Lorraine, F-54000 Nancy, France.

Jean-Dominique de Korwin (JD)

Département de Médecine Interne et Immunologie Clinique, CHRU de Nancy, 54000 Nancy, France.

Pierre Feugier (P)

Services d'Hématologie Clinique et Biologique, CHRU de Nancy, Université de Lorraine, F-54000 Nancy, France.

Julien Broséus (J)

Services d'Hématologie Clinique et Biologique, CHRU de Nancy, Université de Lorraine, F-54000 Nancy, France.

Xavier Troussard (X)

Laboratoire d'Hématologie, CHU de Caen, 14033 Caen, France.

Jean-François Lesesve (JF)

Services d'Hématologie Clinique et Biologique, CHRU de Nancy, Université de Lorraine, F-54000 Nancy, France.

Classifications MeSH